GILEAD SCIENCES, INC.
GILD · CIK 0000882095 · Biological Products, (No Diagnostic Substances)
About GILEAD SCIENCES, INC.
We operate in more than 35 countries worldwide, with headquarters in Foster City, California. Our Business Products We have transformed care for people around the world by discovering, developing and delivering innovative medicines to address unmet medical needs in virology, oncology and other therapeutic areas.
Business information sourced from SEC annual filing filed Feb 24, 2026. Business descriptions reflect the cited filing and may not describe subsequent changes.
Company identification is based on SEC registration information. Financial figures are sourced from SEC filings.
Financial highlights
Latest qualifying annual SEC observations · USDHistorical financial performance
USD billions · Annual SEC observations · Choose a metric
Each metric uses a consistent SEC accounting concept when available. Fiscal year-end dates may differ across metrics. Negative values are displayed with a minus sign.
Annual financial history
USD · Exact fiscal period ends| Period ended | Revenue | Net income | Operating income | Assets | Liabilities | Cash | Operating cash flow | Net margin |
|---|---|---|---|---|---|---|---|---|
| Dec. 31, 2025 | $29.44B | $8.51B | $10.02B | $59.02B | — | — | $10.02B | 28.9% |
| Dec. 31, 2024 | $28.75B | $480.00M | $1.66B | $59.00B | — | — | $10.83B | 1.7% |
| Dec. 31, 2023 | $27.12B | $5.66B | $7.60B | $62.12B | — | — | $8.01B | 20.9% |
| Dec. 31, 2022 | $27.28B | $4.59B | $7.33B | $63.17B | — | $5.41B | $9.07B | 16.8% |
| Dec. 31, 2021 | $27.30B | $6.22B | $9.92B | $67.95B | — | $5.34B | $11.38B | 22.8% |
| Dec. 31, 2020 | $24.69B | $123.00M | $4.07B | $68.41B | — | $6.00B | $8.17B | 0.5% |
| Dec. 31, 2019 | $22.45B | $5.39B | $4.29B | $61.63B | — | $11.63B | $9.14B | 24.0% |
| Dec. 31, 2018 | $22.13B | $5.46B | $8.20B | $63.68B | — | $17.94B | $8.40B | 24.7% |
A dash indicates unavailable or nonmatching period data. Figures are SEC observations, not estimates.
Company information
- Registered name
- GILEAD SCIENCES, INC.
- Ticker symbol
- GILD
- CIK
- 0000882095
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC SIC code
- 2836
- Fiscal year end (MMDD)
- 1231
- Last SEC synchronization
- Nov 7, 2026 17:58 UTC
- Headquarters / business address
- 333 LAKESIDE DR
FOSTER CITY, CA 94404 - Mailing address
- 333 LAKESIDE DR
FOSTER CITY, CA 94404 - Business phone
- 6505743000
Company contact information is drawn from SEC submissions, where reported, and may not reflect current operating locations. Last company information check: Nov 7, 2026 20:22 UTC. Official website, business descriptions and executive details require separate verification.
Latest SEC filings
Browse filings →| Form | Filed | Report period | Official source |
|---|---|---|---|
| 4 | Nov. 6, 2026 | Nov. 4, 2026 | View SEC filing ↗ |
| 4 | Nov. 2, 2026 | Oct. 30, 2026 | View SEC filing ↗ |
| 4 | Oct. 16, 2026 | Oct. 15, 2026 | View SEC filing ↗ |
| 4 | Oct. 16, 2026 | Oct. 15, 2026 | View SEC filing ↗ |
| 4 | Oct. 2, 2026 | Oct. 1, 2026 | View SEC filing ↗ |
| 4 | Sept. 23, 2026 | Sept. 22, 2026 | View SEC filing ↗ |
| 4 | Sept. 16, 2026 | Sept. 15, 2026 | View SEC filing ↗ |
| 4 | Sept. 16, 2026 | Sept. 15, 2026 | View SEC filing ↗ |
| 4 | Sept. 11, 2026 | Sept. 10, 2026 | View SEC filing ↗ |
| 4 | Sept. 11, 2026 | Sept. 10, 2026 | View SEC filing ↗ |
| 4 | Sept. 11, 2026 | Sept. 10, 2026 | View SEC filing ↗ |
| 4 | Sept. 11, 2026 | Sept. 10, 2026 | View SEC filing ↗ |
| 4 | Sept. 11, 2026 | Sept. 10, 2026 | View SEC filing ↗ |
| 4 | Sept. 2, 2026 | Sept. 1, 2026 | View SEC filing ↗ |
| 4 | Aug. 27, 2026 | Aug. 26, 2026 | View SEC filing ↗ |
| 4 | Aug. 21, 2026 | Aug. 20, 2026 | View SEC filing ↗ |
| 4 | Aug. 18, 2026 | Aug. 17, 2026 | View SEC filing ↗ |
| 4 | Aug. 18, 2026 | Aug. 17, 2026 | View SEC filing ↗ |
| 4 | Aug. 11, 2026 | Aug. 10, 2026 | View SEC filing ↗ |
| 4 | Aug. 4, 2026 | Aug. 3, 2026 | View SEC filing ↗ |
Financial data is provided for informational purposes, not investment advice. Observations may include restatements; review original SEC filings before making decisions.